FDA approves Teva’s Ajovy autoinjector for treatment of migraine

pharmafile | January 29, 2020 | News story | Research and Development, Sales and Marketing |  FDA, Teva, ajovy, migraine, pharma 

Israeli pharma firm Teva has revealed that the FDA has chosen to award approval to its autoinjector device for the delivery of its Ajovy (fremanezumab-vfrm) solution, used to treat patients with migraine.

The approval means that US patients will now have access to a delivery option which lets them self-administer the drug. The device is expected to be made available “in the coming months”.

“The approval of the Ajovy autoinjector is another important step forward for Teva and the migraine community,” remarked Brendan O’Grady, Executive Vice President, North America Commercial at Teva. “Ajovy is the only FDA-approved anti-CGRP that offers the flexibility of quarterly (675 mg) or monthly (225 mg) dosing options, and we are pleased that patients and their healthcare providers will be able to decide if an autoinjector is the right administration option for their needs.”

Matt Fellows